Physician profile
Michael Gober
NPI 1154514131
$5,153.72
in general payments reported to CMS, 2019-2025
16 companies · $3,897 in 2025
The $3,897 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $38.71 · 2021: $101 · 2022: $161 · 2023: $326 · 2024: $452 · 2025: $3,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,340 · Food and Beverage: $1,298 · Travel and Lodging: $37.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,340.00 |
| Food and Beverage | $1,297.54 |
| Travel and Lodging | $37.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $3,491.37 | 2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $672.74 | 2019-2025 | |
| Abbvie INC. | $443.21 | 2019-2025 | |
| Janssen Biotech, INC. | $125.87 | 2019-2025 | Tremfya |
| Pfizer INC. | $89.80 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $57.99 | 2022-2025 | Dupixent |
| Amgen INC. | $54.41 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $40.99 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $35.77 | 2019-2025 | Anzupgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.56 | 2024 | Spevigo |
| Incyte Corporation | $24.86 | 2021 | |
| Strata Skin Sciences, INC. | $24.77 | 2024 | Xtrac |
| Almirall LLC | $23.06 | 2025 | Seysara |
| Dermavant Sciences, INC. | $14.01 | 2024 | Vtama |
| Epi Health, LLC | $12.16 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gober listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.